Nitric oxide up-regulates endothelial expression of angiotensin II type 2 receptors

Biochem Pharmacol. 2016 Jul 15:112:24-36. doi: 10.1016/j.bcp.2016.05.011. Epub 2016 May 26.

Abstract

Increasing vascular NO levels following up-regulation of endothelial nitric oxide synthase (eNOS) is considered beneficial in cardiovascular disease. Whether such beneficial effects exerted by increased NO-levels include the vascular renin-angiotensin system remains elucidated. Exposure of endothelial cells originated from porcine aorta, mouse brain and human umbilical veins to different NO-donors showed that expression of the angiotensin-II-type-2-receptor (AT2) mRNA and protein is up-regulated by activation of soluble guanylyl cyclase, protein kinase G and p38 mitogen-activated protein kinase without changing AT2 mRNA stability. In mice, endothelial-specific overexpression of eNOS stimulated, while chronic treatment with the NOS-blocker l-nitroarginine inhibited AT2 expression. The NO-induced AT2 up-regulation was associated with a profound inhibition of angiotensin-converting enzyme (ACE)-activity. In endothelial cells this reduction of ACE-activity was reversed by either the AT2 antagonist PD 123119 or by inhibition of transcription with actinomycin D. Furthermore, in C57Bl/6 mice an acute i.v. bolus of l-nitroarginine did not change AT2-expression and ACE-activity suggesting that inhibition of ACE-activity by endogenous NO is crucially dependent on AT2 protein level. Likewise, three weeks of either voluntary or forced exercise training increased AT2 expression and reduced ACE-activity in C57Bl/6 but not in mice lacking eNOS suggesting significance of this signaling interaction for vascular physiology. Finally, aortic AT2 expression is about 5 times greater in female as compared to male C57Bl/6 and at the same time aortic ACE activity is reduced in females by more than 50%. Together these findings imply that endothelial NO regulates AT2 expression and that AT2 may regulate ACE-activity.

Keywords: Angiotensin II type 2 receptor; Angiotensin converting enzyme 1; Endothelial nitric oxide synthase; Exercise; Nitric oxide.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Endothelial Cells / drug effects*
  • Endothelial Cells / metabolism
  • Enzyme Inhibitors / pharmacology
  • Female
  • Human Umbilical Vein Endothelial Cells
  • Humans
  • Male
  • Mice, Inbred C57BL
  • Mice, Transgenic
  • Motor Activity / drug effects
  • Motor Activity / genetics
  • Nitric Oxide / metabolism*
  • Nitric Oxide Donors / pharmacology*
  • Nitric Oxide Synthase Type III / antagonists & inhibitors
  • Nitric Oxide Synthase Type III / genetics
  • Receptor, Angiotensin, Type 2 / genetics*
  • Renin-Angiotensin System / drug effects
  • Swine
  • Up-Regulation

Substances

  • Enzyme Inhibitors
  • Nitric Oxide Donors
  • Receptor, Angiotensin, Type 2
  • Nitric Oxide
  • Nitric Oxide Synthase Type III